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Abstract Due to the limited experience with capecitabine
plus docetaxel (XT) combination in the first-line treatment
of metastatic breast cancer in Hungary, the main objective of
the study was to analyze the effectiveness and tolerability of
XT therapy. A prospective, open-label, non-randomized, sin-
gle-arm, multicenter, observational study was designed. All
female patients were eligible whose metastatic breast cancer
could be treated with the XT protocol according to the sum-
mary of product characteristics of the drugs. The median pro-
gression free survival was 9.9 ± 3.0 months. Time to treatment
failure was 4.6 ± 5.1 months on average. The overall response
rate was 28.9 %, the clinical benefit rate was 73.3 %. The
treatment was discontinued in 35.6 % of patients due to dis-
ease progression and in 20.0 % due to adverse events (AE). 33
patients with a total of 73 AEs have been reported, and 13 of
them had serious adverse events (SAE). The efficacy and the
safety profile of XT chemotherapy proven in the study are
consistent with the results demonstrated in randomized trials.
First-line XT chemotherapy effectively improves the PFS in
metastatic breast cancer.
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Introduction
Capecitabine is a derivative of 5′-deoxy-S-fluoro uridine carbon-
ate, which is absorbed from the gastrointestinal tract invariably as
a prodrug [1]. To themetabolism of capecitabine into active 5-FU,
three activation steps are needed [2]. In the final process step, the
thymidine phosphorylase (TP) enzyme plays a key role in creating
the active form. The enzyme is present in normal and tumor cells,
however, since the expression of TP inmost tumor tissues ismuch
higher than in normal tissues, the prodrug’s activation and con-
centration is increased in cancers as compared to that in healthy
tissues. This results in relatively selective effect and lower system-
ic toxicity than the use of intravenous 5-FU [3–5].
In addition to the selective activation of capecitabine in
tumors [1, 2], synergy with other anticancer agents such
as the taxanes is reported [6]. Docetaxel blocks the
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breakdown of the microtubule system allowing cell divi-
sion and multiplying, resulting in cell death [8]. It also
affects the development of non-cancer cells such as the
blood cells, which may cause side effects. According to
human cancer xenograft studies, Docetaxel induces TP
activity in cancer cells, thereby enhancing the efficacy
of capecitabine, thus potentiating the inhibition of tumor
growth in colon and breast cancer models [6].
Capecitabine (Xeloda®, Roche) plus docetaxel (XT) ther-
apy is a reasonable choice for the treatment of metastatic
breast cancer (MBC) patients who have previously received
anthracyclines [7]. The main objective of the XEBRA study
was to assess safety and efficacy of XT treatment under real-
life circumstances.
Patients and Methods
All the procedures followed were in full accordance with the
ethical standards of the responsible committees on human
experimentation (institutional and national) and with the
Helsinki declaration. All patients gave informed consent be-
fore enrollment into the study authorized by the National and
Regional Ethics Committees.
Study Design
XEBRAwas a prospective, open-label, non-randomized, sin-
gle-arm, multicenter, observational study run in Hungary. All
female patients whose metastatic breast cancer could be treat-
ed with the XT protocol according to the summary of product
characteristics of the drugs were eligible.
The data after enrollment were prospectively collected
within the frame of routine oncology care of metastatic breast
cancer (MBC) patients in 11 Hungarian oncology centers. All
assessments and interventions were done in compliance with
the international and institutional protocols. The choice of
therapy was decided by an oncologist team prior to inclusion.
At the first consultation, demographic data (date of birth,
height, weight, performance status, menopausal status), the
medical history and the breast cancer-specific data (date of
diagnosis, initial stage, immune-histological parameters, sur-
gery, radiotherapy and systemic therapy, disease-free interval
after adjuvant therapy [DFI], date of detection and localization
of metastases) were collected as extracted from the patient
files. Thereafter, all the informations on the therapy with the
XT regimen including efficacy and adverse events were col-
lected from the patient files.
Follow-up was continued until the disease progression or
the patient’s death, withdrawal of the consent, loss of contact
with the patient or the closure of the study, depending on the
earliest event occurred.
The number of completed capecitabine and docetaxel cy-
cles, date of last dose, reason for treatment discontinuation,
dose modifications, response to therapy, date of progression
and/or death, impact of treatment on initial symptoms and
adverse events (AEs) occurring during therapy were
registered.
Inclusion and Exclusion Criteria
The study had no specific inclusion criteria. All the patients
could take part in the observational study, who were found
suitable to the XT regimen according to the official prescrip-
tion conditions: HER2-negative MBC patients who have pre-
viously received either adjuvant or neoadjuvant chemotherapy
with standard regimens containing an anthracycline agent or
who have started first-line XT chemotherapy within 3 months
prior to enrollment.
The study had no specific exclusion criteria, but the trial
excluded patients in whom there was a contraindication to the
use of capecitabine included in prescription, such as severe
and unexpected reactions to fluoropyrimidine therapy in his-
tory, hypersensitivity to fluorouracil, capecitabine, known
dihydropyrimidine dehydrogenase (DPD) deficiency, preg-
nancy and lactation, severe leucopenia, neutropenia, or throm-
bocytopenia, severe liver injury, severe renal impairment (cre-
atinine clearance below 30 ml / min), treatment with
sorivudine or chemical analogues, or if there was a contrain-
dication to any drug in the combination.
Study Endpoints
The primary endpoint was median progression free survival
(PFS). PFS was defined as the time between the start of study
treatment and the detection of disease progression or death.
Secondary endpoints included time to treatment failure (TTF).
TTF was defined as the time between the start and stop of all
study medication due to any reason including disease progres-
sion, toxicity or death of the patient), overall response rate
(ORR), clinical benefit rate (CBR), dose modification and
mean duration of capecitabine treatment, and its toxicity pro-
file. Serious adverse events (SAEs) were classified according
to the current version of the Medical Dictionary for
Regulatory Activities (MedDRA).
Statistical Analyses
Data evaluation of demographics, breast tumor-specific med-
ical history, XT chemotherapy, changes due to treatment, sec-
ondary endpoints and adverse events was done using descrip-
tive statistics. The analysis of PFS was performed using the
Kaplan-Meier method.
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Results
Patient- and Tumor-Related Characteristics
Between December 2012 and December 2013, altogether 46
patients were enrolled into the study from 11 of 15 opened
centers. Patient- and tumor-related characteristics were ana-
lyzed for 45 eligible patients (Table 1), while 1 additional
ineligible patient was included in safety analyses only.
The mean ± SD age was 58.6 ± 11.4 years (median:
59.0 years, range 35–83 years). Most patients (n = 35,
79.5 %) were postmenopausal, and 15 (33.3 %) were
>65 years old at enrollment.
The mean ± SD age at the initial diagnosis of breast cancer
was 53.2 ± 11.2 years (median: 54.0 years, range: 31–81 years)
of the population, and 22 patients (48.9 %) had stage 3 disease
at that time. Histological diagnosis was invasive ductal carci-
noma in 40 patients (88.9 %), invasive lobular cancer in 4
cases (8.9%), while in 1 (2.2%), mixed carcinomawas found.
Three-quarters (77.8 %) were estrogen receptor (ER)-positive
and 60.0 % progesterone receptor (PR)-positive, 9 (20.5 %)
were triple negative. Most patients (36, 80.0 %) underwent
surgical treatment, and in 34 (75.6 %), radiation therapy was
performed. All patients received chemotherapy in the adjuvant
and/or neoadjuvant setting (Table 2). In one case no data were
available. 29 patients (64.4 %) also received adjuvant endo-
crine treatment. Half of the patients (48.9%) hadDFI >2 years,
and one-third (33.3 %) showed a DFI <1 year.
XT Treatment
In 27 patients (60 %) capecitabine was orally administered at
an initial dose of 1250 mg/m2 twice a day on days 1–14,
followed by one week medication-free period. Due to the
observational design of the study, no accurate data were avail-
able on 18 patients as regards the dose of capecitabine. At the
beginning of the study, 80.0 % of the patients (36 patients)
received 75 mg/m2 docetaxel treatment in intravenous infu-
sion once daily on day 1 every 3 weeks, however, for similar
reasons, no exact information on the dose of docetaxel was
given in 8 cases. Supportive therapy was applied according to
institutional protocols.
Efficacy
The best tumor response achieved was complete remission in
1 case, and partial remission (PR) was obtained in 12 cases
(26.7 %); stable disease occurred in 20 patients (44.4 %).
Disease progression (PD) was reported in 18 cases (40.0 %).
Thus, ORRwas 28.9%, while CBRwas 73.3%. According to
the patient files, initial tumor-related symptoms improved or
disappeared in 16 patients (35.6 %), in 19 cases (42.2 %),
however, deteriorated or persisted. There was no such data
available in 10 patients (Table 3).
The median PFS was 9.9 ± 3.0 months (95 % CI: 4.1–15.7)
(Fig. 1). TTF was 4.6 ± 5.1 months on average (median: 3.00,
range: 0–21).
Table 1 Baseline patient and tumor characteristics
Characteristics Patients
(N = 45)
N %
Stage 0 1 2.2
1 8 17.8
2 14 31.1
3 22 48.9
ER Negative (≤10 %) 10 22.2
Positive (>10 %) 35 77.8
PR Negative (≤10 %) 18 40.0
Positive (>10 %) 27 60.0
Disease-free/ recurrence-free period ≤1 year 15 33.3
>1 year and ≤2 years 7 15.6
>2 years 22 48.9
No data available 1 2.2
Localization of metastases Bone 19 42.2
Lung 18 40.0
Pleura 13 28.9
Liver 16 35.6
Skin 2 4.4
Other (3 cases: no data
available, 8 cases:
lymph node)
16 38.1
European Cooperative Oncology
Group (ECOG) performance
status score
0 26 57.8
1 16 35.6
2 2 4.4
No data available 1 2.2
Table 2 Chemotherapeutic regimens applied in the study population in
the adjuvant/neoadjuvant setting
Chemotherapeutic regimens Number of patients n = 45 (%)
AC 3 (6.7)
EC 3 (6.7)
FAC 6 (13.3)
FEC 10 (22.2)
FEC100, then docetaxel 2 (4.4)
ED 4 (8.9)
AC, then paclitaxel 2 (4.4)
TAC 8 (17.8)
Other 7 (15.6)
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Safety
The patients received 6.24 ± 4.80 cycles of capecitabine and
6.20 ± 5.12 cycles of docetaxel on average, but the number of
treatment cycles showed high variability (range: 1–26 and 1–
25, respectively). The reason for treatment discontinuation in
most cases was disease progression or physician’s decision by
considering the risks of therapy continuation (Table 4). Dose
reduction was applied for capecitabine in 20 cases (44.4 %),
and docetaxel in 15 cases (33.3 %), due to AE in 14 patients
(70.0 %) and 10 patients (63.7 %), respectively.
The most common adverse events were hand foot syn-
drome (26.1 %), neutropenia (21.7 %), mucositis (8.7 %),
and diarrhea (6.5 %). During the study, altogether 73 AEs
among 33 patients have been reported, of which 13 (17.8 %)
were considered as SAE. Fifteen of the reported AEs (20.6 %)
were typical for the XT combination treatment, while 21
(28.8 %) and 26 (35.6 %) events were attributed to capecita-
bine and docetaxel, respectively. The AEs with an incidence
of >5 % was found to be 35 and affected 21 patients (45.7 %),
as shown in Table 5. Seventeen AEs (23.3 %) led to cessation
of therapy, 9 of which were related to capecitabine, and an-
other 8 to docetaxel. Twenty-four (32.9 %) of the AEs lead to
reduction of either capecitabine (n = 14) or docetaxel (n = 10)
doses. 52 of the reported AEs (71.2 %) required therapeutic
intervention, while 21 (28.8 %) not. Most AEs resolved or
improved (59 events, 80.8 %), usually without sequelae (44
events, 60.3 %). Until study completion the outcome of 14
events (19.2 %) remained the same or worsened (Table 6).
SAEs are summarized in Table 7. During the study, a total of
13 SAEs were reported in 8 patients. In 4 patients 1 SAE each,
in 3 patients 2 SAEs, and in another patient 3 SAEs were
reported. According to the consideration of the investigator, 3
SAEs (23.1 %) were related to the XT combination, 3 other
events (23.1 %), were related to capecitabine, and 2 events
(15.4 %) to docetaxel therapy. The majority of SAEs (8 events,
61.5 %) resolved without sequelae. One docetaxel treatment-
related SAE (neutropenia) had fatal outcome. Three other pa-
tients died during the study; none of these deaths was associated
with capecitabine or docetaxel treatment.
Table 3 Best tumor response and changes in the initial tumor-related
symptoms among the included patients during first-line capecitabine-do-
cetaxel therapy
Response to capecitabine-docetaxel treatment Patients (N = 45)
N %
Best tumor response Complete Remission (CR) 1 2.2
Partial Remission (PR) 12 26.7
Stable Disease (SD) 20 44.4
Progressive Disease (PD) 12 26.7
Tumor-related symptoms Improved 14 31.1
Ceased 2 4.4
Persisted 17 37.8
Deteriorated 2 4.4
Unknown 10 22.2
Fig. 1 Kaplan-Meier analysis of
progression-free survival in
patients treated with first-line XT
chemotherapy; median
PFS = 9.9 ± 3.0 months (95 % CI:
4.1–15.7)
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Discussion
The significant anticancer effect of combined XT therapy was
first demonstrated in a phase I trial in patients with advanced
solid tumors [8]. The study applied a 3-weekly regimen of
capecitabine 1250 mg/m2 twice daily, days 1–14, and doce-
taxel 75 mg/m2 on day 1, which was well tolerated, further-
more, in six patients allowed the delivery of ≥23 cycles. This
regimen was then evaluated in the large pivotal phase III trial
resulting in a time to tumor progression (TTP) of 6.1 months,
indicating that second- or third-line XT therapy is highly ef-
fective for patients with anthracycline-pretreated MBC. XT
combination was significantly superior to docetaxel mono-
therapy, with significantly superior ORR, TTP, and OS as
compared to single-agent docetaxel [9]. The subsequent ran-
domized trials in first-, second- and third-line settings using
the same regimen achieved TTP/PFS of 7.9–10 months, me-
dian overall survival (OS) of 16.4–28 months and ORR of
38.9–68 % [10–13]. Despite the differences in patient popu-
lations, the regimens and the response criteria applied, our
data are comparable with these results.
In our study, dose reduction of capecitabine and docetaxel
was necessary in 44.4 % and 33.3 % of the patients, respec-
tively. In the pivotal phase III trial [9] the results of patients
undergoing early dose reduction, showed unaltered efficacy of
the XT combination. Harvey et al. [14] recommended that in
patients older than 60 years, a 25 % reduction of the starting
dose should be pondered and that a further decrease in the
dose of docetaxel to 55–60 mg/m2 may lead to further benefit
regarding the side effects without adverse impact on survival.
These data allowed the determination of the most favorable-
dose regimen with still high antitumor activity. In phase II
clinical trials [12, 15] capecitabine 825 mg/m2 twice daily,
on days 1–14 plus docetaxel 75 mg/m2 resulted in a median
PFS of 5.8–8.5 month, an ORR of 37.4–74 % and a median
OS of 15.1–28.6 months. In the study of the Hellenic
Oncology Group [16] 950 mg/m2 capecitabine twice daily
was combined with docetaxel 75 mg/m2. ORR was 53 %,
PFS was 11 months and median OS was 35.7 months.
Michalaki et al. [17] found a PFS of 8 months, an ORR of
42 % and a median OS of 23 months in patients with MBC,
receiving first-line XT therapy of the same regimen. Seidman
et al. [18] and Bachelot et al. [19] reported an 8.9–12.4months
PFS, respectively, when applying 1000 mg/m2 capecitabine
twice daily and the usual dose of docetaxel; the median OS
was 23.3months. Bachelot et al. detected anORR of 64% and
a 2-year OS of 68 % [19]. Yu et al. evaluated that capecitabine
in a dose of 1000 mg/m2 twice a day on days 1–14 combined
with docetaxel 35 mg/m2 on days 1 and 8 yielded a PFS of
8.3 months [20]. The ORR was 12.27 % and the 1-year me-
dian OS was 81 %. Gradishar [21] and Blum et al. [22]
ascertained that the combination of capecitabine at a reduced
dose and 3-weekly or weekly paclitaxel has a high efficacy
and a more favorable safety profile.
In our study, neutropenia and hand-foot syndrome (HFS)
were the most common adverse events, followed by mucositis
and diarrhea. These adverse effects are well known from both
the previous studies [7–17] and everyday practice. In the piv-
otal phase III trial gastrointestinal side effects andHFS occurred
more frequently in patients receiving combined chemotherapy
[9]. However, myalgia, arthralgia, neutropenic fever and sepsis
were more commonwhen docetaxel was used as a single agent.
In the studies applying lower doses of capecitabine, HFS and
neutropenia were the most common adverse events [17]. At the
registered dose, grade 3–4 diarrhea was detected in 18 % of
patients [9–11] while in the trials testing a reduced dose of
capecitabine [15–17] it was reported in 2–7 % of the cases.
At the 1250 mg/m2 twice a day dose of capecitabine, 18–
26 % of the patients developed grade 3 HFS [9–11], whereas
Table 5 Adverse events occurring in >5 % of the cases (n = 46)
Adverse event Number of patients (%) Occasion
Neutropenia 10 (21.7) 14
Diarrhea 3 (6.5) 4
Mucositis 4 (8.7) 4
Hand-foot syndrome 12 (26.1) 13
Table 6 The outcome of the adverse events in the ITT population
(n = 46)
Outcome of the adverse event Number of adverse events (%)
Completely recovered 44 (60.3)
Recovered with sequelae 4 (5.5)
Improved 11 (15.1)
Persistent 7 (9.6)
Deteriorated 3 (4.1)
Fatal 4 (5.5)
Table 4 Reasons for treatment (capecitabine vs. docetaxel)
discontinuation in the patient population
Reason for treatment discontinuation Number of patients (%)
Capecitabine Docetaxel
Disease progression 16 (35.6) 12 (26.7)
Death due to other reason (neutropenia) 1 (2.2) 1 (2.2)
Adverse event 9 (20.0) 8 (17.8)
Decision of the physician 12 (26.7) 15 (33.3)
Withdrawal of consent 2 (4.4) 3 (6.7)
The contact with the patient was lost 3 (6.7) 3 (6.7)
Decision of the sponsor 2 (4.4) 1 (2.2)
No data available 0 (0.0) 2 (4.4)
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in the studies examining decreased doses [15–17], 4–13 % on-
ly. In general, the safety profile of the XT regimen is better
when given at a reduced dose, and side effects are well con-
trolled with either medical interventions or dose reductions.
The aim of our observational study was to collect experi-
ences with the administration of XT chemotherapy in routine
practice in Hungarian oncology centres. A limitation of our
study was the small size of the population included. Although
the study design did not allow the evaluation of the safety,
tolerability and efficacy of XT treatment in comparison with
a control arm, since these data are well known from large
phase II-III clinical studies [9–20], the main goal was the
introduction of this new regimen into routine practice. Our
findings raise the attention to the importance of appropriate
patient selection and toxicity management.
In conclusion, first-line XT therapy effectively improves
the PFS of anthracycline-pretreated patients with rapidly
progressing HER2-negative breast cancer, visceral metastases
and a good physical status. The AEs appearing during treat-
ment are well manageable with modifications in the dose of
either capecitabine or docetaxel, significantly improving the
tolerability of therapy but without impairing its efficacy.
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